These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 24736581

  • 1. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
    Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N.
    Br J Cancer; 2014 May 13; 110(10):2441-9. PubMed ID: 24736581
    [Abstract] [Full Text] [Related]

  • 2. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
    Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F.
    Fundam Clin Pharmacol; 2018 Feb 13; 32(1):98-107. PubMed ID: 29055166
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.
    J Clin Oncol; 2009 Sep 01; 27(25):4068-75. PubMed ID: 19652072
    [Abstract] [Full Text] [Related]

  • 4. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
    Sabanathan D, Zhang A, Fox P, Coulter S, Gebski V, Balakrishnar B, Chan M, Liddle C, Gurney H.
    Cancer Chemother Pharmacol; 2017 Aug 01; 80(2):385-393. PubMed ID: 28667354
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
    Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP.
    Br J Clin Pharmacol; 2017 Oct 01; 83(10):2195-2204. PubMed ID: 28500677
    [Abstract] [Full Text] [Related]

  • 7. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
    Kloth JS, Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, Burger H, Chaves I, Wiemer EA, van der Horst GT, Mathijssen RH.
    Clin Pharmacokinet; 2015 Aug 01; 54(8):851-8. PubMed ID: 25647628
    [Abstract] [Full Text] [Related]

  • 8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 01; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 9. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
    Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF.
    Cancer; 2014 Apr 15; 120(8):1194-202. PubMed ID: 24474568
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.
    J Clin Oncol; 2010 Oct 10; 28(29):4513-20. PubMed ID: 20837944
    [Abstract] [Full Text] [Related]

  • 11. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
    Szałek E, Karbownik A, Sobańska K, Połom W, Grabowski T, Wolc A, Matuszewski M, Grześkowiak E.
    Eur Rev Med Pharmacol Sci; 2014 Aug 10; 18(16):2393-9. PubMed ID: 25219843
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW.
    Cancer Chemother Pharmacol; 2016 Jun 10; 77(6):1193-200. PubMed ID: 27103123
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
    Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW.
    J Clin Oncol; 2019 Feb 10; 37(5):411-418. PubMed ID: 30586316
    [Abstract] [Full Text] [Related]

  • 15. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR.
    Clin Cancer Res; 2016 Jul 01; 22(13):3209-17. PubMed ID: 26864210
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR.
    Eur J Cancer; 2017 Nov 01; 85():78-85. PubMed ID: 28892776
    [Abstract] [Full Text] [Related]

  • 17. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
    Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M.
    Clin Chim Acta; 2009 Jun 27; 404(2):134-9. PubMed ID: 19341717
    [Abstract] [Full Text] [Related]

  • 18. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S.
    Br J Cancer; 2010 Jun 08; 102(12):1699-706. PubMed ID: 20485286
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS.
    J Clin Oncol; 2006 Sep 01; 24(25):4092-9. PubMed ID: 16943527
    [Abstract] [Full Text] [Related]

  • 20. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
    Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY.
    Cancer Chemother Pharmacol; 2009 Sep 01; 64(4):691-706. PubMed ID: 19169880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.